Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Synovial Sarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986)
Phase 1/2
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Active, not recruiting
Phase 1/2
Roswell Park Cancer Institute
Active, not recruiting
Last update posted :
06/13/2024
Initiation :
07/14/2017
Primary completion :
03/04/2021
Completion :
07/14/2032
BRAF • CTAG1B
|
BRAF mutation
|
azacitidine • cyclophosphamide • decitabine • cyclophosphamide intravenous
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (NCT05848739)
Phase 1
Sapience Therapeutics
Sapience Therapeutics
Recruiting
Phase 1
Sapience Therapeutics
Recruiting
Last update posted :
06/05/2024
Initiation :
06/05/2023
Primary completion :
05/31/2026
Completion :
05/31/2027
PD-L1 • MSI • BRCA
|
PD-L1 expression • MSI-H/dMMR • BRCA mutation
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium • ST316
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 (NCT06083883)
Phase 1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Recruiting
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
06/04/2024
Initiation :
03/27/2024
Primary completion :
11/30/2026
Completion :
11/30/2028
HLA-A • CTAG1B • SSX1
|
HLA-A*02
|
cyclophosphamide • fludarabine IV
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (NCT02601950)
Phase 2
Epizyme, Inc.
Epizyme, Inc.
Completed
Phase 2
Epizyme, Inc.
Completed
Last update posted :
04/29/2024
Initiation :
12/22/2015
Primary completion :
02/26/2024
Completion :
02/26/2024
CD34 • SS18
|
SMARCA4 mutation
|
Tazverik (tazemetostat)
SPEARHEAD-3 Pediatric Study (NCT05642455)
Phase 1/2
Adaptimmune
Adaptimmune
Recruiting
Phase 1/2
Adaptimmune
Recruiting
Last update posted :
04/24/2024
Initiation :
09/01/2023
Primary completion :
10/01/2026
Completion :
07/30/2038
HLA-A • MAGEA4
|
HLA-A*02 • HLA-A2 positive • MAGEA4 expression
|
Tecelra (afamitresgene autoleucel)
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-02) (NCT04483778)
Phase 1
Seattle Children's Hospital
Seattle Children's Hospital
Active, not recruiting
Phase 1
Seattle Children's Hospital
Active, not recruiting
Last update posted :
04/23/2024
Initiation :
07/13/2020
Primary completion :
12/01/2025
Completion :
12/01/2040
CD276
|
CD276 expression • CD19 expression
|
Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (STRIvE-01) (NCT03618381)
Phase 1
Seattle Children's Hospital
Seattle Children's Hospital
Recruiting
Phase 1
Seattle Children's Hospital
Recruiting
Last update posted :
04/09/2024
Initiation :
06/18/2019
Primary completion :
06/01/2025
Completion :
06/01/2040
EGFR
|
EGFR expression
|
EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD-1) (NCT04044768)
Phase 2
Adaptimmune
Adaptimmune
Recruiting
Phase 2
Adaptimmune
Recruiting
Last update posted :
02/19/2024
Initiation :
08/13/2019
Primary completion :
10/10/2021
Completion :
04/01/2038
HLA-A • MAGEA4
|
HLA-A*02 • MAGEA4 expression
|
Tecelra (afamitresgene autoleucel)
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (NCT04995003)
Phase 1
Baylor College of Medicine
Baylor College of Medicine
Recruiting
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
01/25/2024
Initiation :
12/07/2021
Primary completion :
12/31/2027
Completion :
12/31/2040
HER-2
|
HER-2 positive • HER-2 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922)
Phase 1
Adaptimmune
Adaptimmune
Active, not recruiting
Phase 1
Adaptimmune
Active, not recruiting
Last update posted :
01/22/2024
Initiation :
05/15/2017
Primary completion :
12/27/2022
Completion :
09/01/2032
HLA-A • MAGEA4
|
HLA-A*02 • HLA-A2 positive
|
Tecelra (afamitresgene autoleucel)
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer (NCT05492682)
Phase 1
Valo Therapeutics Oy
Valo Therapeutics Oy
Recruiting
Phase 1
Valo Therapeutics Oy
Recruiting
Last update posted :
01/12/2024
Initiation :
02/02/2023
Primary completion :
06/01/2025
Completion :
09/01/2025
PD-L1
|
Keytruda (pembrolizumab) • cyclophosphamide • PeptiCRAd-1
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217)
Phase 1
University Health Network, Toronto
University Health Network, Toronto
Active, not recruiting
Phase 1
University Health Network, Toronto
Active, not recruiting
Last update posted :
12/08/2023
Initiation :
09/01/2016
Primary completion :
09/01/2024
Completion :
09/01/2024
HLA-A • CTAG1B
|
HLA-A*02 • CTAG1B expression
|
cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma (NCT03250325)
Phase 1/2
Takara Bio Inc.
Takara Bio Inc.
Completed
Phase 1/2
Takara Bio Inc.
Completed
Last update posted :
12/06/2023
Initiation :
09/20/2017
Primary completion :
01/23/2020
Completion :
03/09/2022
HLA-A • CTAG1B
|
HLA-A*02 • CTAG1B expression
|
cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (NCT06094101)
Phase 1/2
University Hospital Tuebingen
University Hospital Tuebingen
Recruiting
Phase 1/2
University Hospital Tuebingen
Recruiting
Last update posted :
11/22/2023
Initiation :
09/19/2023
Primary completion :
06/01/2027
Completion :
09/01/2027
CD8 • CD4
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma (NCT03063632)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
10/25/2023
Initiation :
12/14/2017
Primary completion :
04/08/2021
Completion :
03/14/2023
IFNG • CTAG1B
|
CTAG1B expression
|
Keytruda (pembrolizumab) • Actimmune (interferon gamma-1 b) • Pembroria (pembrolizumab biosimilar)
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (NCT05993299)
Phase 2
GlaxoSmithKline
GlaxoSmithKline
Active, not recruiting
Phase 2
GlaxoSmithKline
Active, not recruiting
Last update posted :
10/16/2023
Initiation :
12/31/2019
Primary completion :
10/12/2022
Completion :
07/01/2024
HLA-A • CTAG1B
|
HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (NCI-2018-00926) (NCT03450122)
Phase 1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Completed
Phase 1
M.D. Anderson Cancer Center
Completed
Last update posted :
10/16/2023
Initiation :
09/13/2018
Primary completion :
12/06/2022
Completion :
12/06/2022
HLA-A • CTAG1B
|
cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (NCT03009201)
Phase 1b
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Completed
Phase 1b
OHSU Knight Cancer Institute
Completed
Last update posted :
08/16/2023
Initiation :
03/10/2017
Primary completion :
10/08/2019
Completion :
06/30/2023
RB1
|
doxorubicin hydrochloride • Kisqali (ribociclib)
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (NCT02452554)
Phase 2
Children's Oncology Group
Children's Oncology Group
Completed
Phase 2
Children's Oncology Group
Completed
Last update posted :
01/13/2022
Initiation :
10/12/2015
Primary completion :
06/30/2017
Completion :
09/30/2021
NCAM1
|
NCAM1 expression
|
lorvotuzumab mertansine (IMGN901)
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (NCT02601937)
Phase 1
Epizyme, Inc.
Epizyme, Inc.
Completed
Phase 1
Epizyme, Inc.
Completed
Last update posted :
12/27/2021
Initiation :
01/07/2016
Primary completion :
10/22/2021
Completion :
10/22/2021
SS18
|
SMARCA4 mutation
|
Tazverik (tazemetostat)
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma (ADP 04511) (NCT01343043)
Phase 1
GlaxoSmithKline
GlaxoSmithKline
Completed
Phase 1
GlaxoSmithKline
Completed
Last update posted :
06/30/2021
Initiation :
09/27/2012
Primary completion :
06/18/2019
Completion :
06/18/2019
HLA-A • CTAG1B
|
HLA-A*02 • CTAG1B expression
|
cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206)
Phase 1/2
Shenzhen BinDeBio Ltd.
Shenzhen BinDeBio Ltd.
Recruiting
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
12/11/2019
Initiation :
03/01/2018
Primary completion :
03/01/2023
Completion :
03/01/2023
MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B
|
HLA-A*02:01 • CD19 expression • HLA-A positive
|
cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy (NCT00004853)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
11/12/2019
Initiation :
03/03/2000
Primary completion :
05/20/2009
Completion :
05/20/2009
CD34
|
CD34 positive
|
Neupogen (filgrastim)
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a (NCT03697824)
Phase 1b/2a
GlaxoSmithKline
GlaxoSmithKline
Withdrawn
Phase 1b/2a
GlaxoSmithKline
Withdrawn
Last update posted :
10/29/2019
Initiation :
02/25/2019
Primary completion :
07/18/2022
Completion :
07/18/2022
HLA-A • CTAG1B • CTAG2
|
HLA-A*02 • CTAG2 expression
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
12/11/2018
Initiation :
06/18/2012
Primary completion :
04/01/2014
Completion :
04/01/2014
mTOR • IR
|
Torisel (temsirolimus) • cixutumumab (IMC A12)
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650)
Phase 1
Shenzhen Second People's Hospital
Shenzhen Second People's Hospital
Unknown status
Phase 1
Shenzhen Second People's Hospital
Unknown status
Last update posted :
08/03/2016
Initiation :
04/01/2015
Primary completion :
12/01/2019
Completion :
12/01/2019
CTAG1B
|
CTAG1B expression • HLA-A2 positive
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (NCT02059850)
Phase 1
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Withdrawn
Phase 1
Fred Hutchinson Cancer Center
Withdrawn
Last update posted :
02/03/2016
Initiation :
07/01/2014
Primary completion :
01/01/2016
Completion :
01/01/2016
CTAG1B
|
CTAG1B expression
|
cyclophosphamide • cyclophosphamide intravenous
Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (NCT01477021)
Phase 1
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Completed
Phase 1
Fred Hutchinson Cancer Center
Completed
Last update posted :
12/11/2014
Initiation :
01/01/2012
Primary completion :
09/01/2013
CTAG1B
|
CTAG1B expression
|
cyclophosphamide • cyclophosphamide intravenous
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login